DE69131422D1 - Gegensinnige hemmer des humanen immunmangel virus (hiv) - Google Patents

Gegensinnige hemmer des humanen immunmangel virus (hiv)

Info

Publication number
DE69131422D1
DE69131422D1 DE69131422T DE69131422T DE69131422D1 DE 69131422 D1 DE69131422 D1 DE 69131422D1 DE 69131422 T DE69131422 T DE 69131422T DE 69131422 T DE69131422 T DE 69131422T DE 69131422 D1 DE69131422 D1 DE 69131422D1
Authority
DE
Germany
Prior art keywords
hiv
rna
human immune
tat
immune virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69131422T
Other languages
English (en)
Other versions
DE69131422T2 (de
Inventor
David Ecker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69131422D1 publication Critical patent/DE69131422D1/de
Publication of DE69131422T2 publication Critical patent/DE69131422T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
DE69131422T 1990-05-11 1991-04-22 Gegensinnige hemmer des humanen immunmangel virus (hiv) Expired - Fee Related DE69131422T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/521,907 US5166195A (en) 1990-05-11 1990-05-11 Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
PCT/US1991/002734 WO1991018004A1 (en) 1990-05-11 1991-04-22 Antisense inhibitors of the human immunodeficiency virus

Publications (2)

Publication Number Publication Date
DE69131422D1 true DE69131422D1 (de) 1999-08-12
DE69131422T2 DE69131422T2 (de) 1999-10-28

Family

ID=24078638

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69131422T Expired - Fee Related DE69131422T2 (de) 1990-05-11 1991-04-22 Gegensinnige hemmer des humanen immunmangel virus (hiv)

Country Status (13)

Country Link
US (2) US5166195A (de)
EP (1) EP0527916B1 (de)
JP (1) JPH0832242B2 (de)
KR (1) KR0149680B1 (de)
AT (1) ATE181960T1 (de)
AU (1) AU651593B2 (de)
BR (1) BR9106440A (de)
CA (1) CA2082631A1 (de)
DE (1) DE69131422T2 (de)
FI (1) FI925103A (de)
HU (1) HUT62912A (de)
NO (1) NO924258L (de)
WO (1) WO1991018004A1 (de)

Families Citing this family (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1223831A (en) 1982-06-23 1987-07-07 Dean Engelhardt Modified nucleotides, methods of preparing and utilizing and compositions containing the same
US5856088A (en) * 1989-07-11 1999-01-05 Gen-Probe Incorporated Detection of human immunodeficiency virus type 1
US6589734B1 (en) 1989-07-11 2003-07-08 Gen-Probe Incorporated Detection of HIV
US6339066B1 (en) 1990-01-11 2002-01-15 Isis Pharmaceuticals, Inc. Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
US20040142899A1 (en) * 1990-01-11 2004-07-22 Isis Pharmaceuticals, Inc. Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
US6753423B1 (en) 1990-01-11 2004-06-22 Isis Pharmaceuticals, Inc. Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
US5635488A (en) * 1991-10-15 1997-06-03 Isis Pharmaceuticals, Inc. Compounds having phosphorodithioate linkages of high chiral purity
US5959096A (en) * 1992-03-16 1999-09-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against human protein kinase C
US5587361A (en) * 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5620963A (en) * 1991-10-15 1997-04-15 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity
US5248670A (en) * 1990-02-26 1993-09-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotides for inhibiting herpesviruses
US6034233A (en) * 1990-05-04 2000-03-07 Isis Pharmaceuticals Inc. 2'-O-alkylated oligoribonucleotides and phosphorothioate analogs complementary to portions of the HIV genome
US5138045A (en) * 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
GB9016973D0 (en) * 1990-08-02 1990-09-19 Medical Res Council Viral growth inhibition
AU652577B2 (en) * 1990-08-14 1994-09-01 Isis Pharmaceuticals, Inc. Inhibition of influenza virus type A, Ann Arbor strain H2N2 by antisense oligonucleotides
GB9020541D0 (en) * 1990-09-20 1990-10-31 Medical Res Council Viral growth inhibition
US5786145A (en) * 1990-09-20 1998-07-28 Medical Research Council Oligonucleotide competitors for binding of HIV RRE to REV protein and assays for screening inhibitors of this binding
US7119184B2 (en) 1991-08-12 2006-10-10 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US6369209B1 (en) 1999-05-03 2002-04-09 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US5576302A (en) * 1991-10-15 1996-11-19 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
US5661134A (en) * 1991-10-15 1997-08-26 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
US5654284A (en) * 1991-10-15 1997-08-05 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating RAF kinase having phosphorothioate linkages of high chiral purity
US5599797A (en) * 1991-10-15 1997-02-04 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5607923A (en) * 1991-10-15 1997-03-04 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
US8153602B1 (en) 1991-11-19 2012-04-10 Isis Pharmaceuticals, Inc. Composition and methods for the pulmonary delivery of nucleic acids
WO1993013114A1 (en) * 1991-12-24 1993-07-08 Isis Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR MODULATING β-AMYLOID
US6153599A (en) * 1992-03-16 2000-11-28 Isis Pharmaceuticals, Inc. Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
US6537973B1 (en) 1992-03-16 2003-03-25 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of protein kinase C
US6117847A (en) * 1992-03-16 2000-09-12 Isis Pharmaceuticals, Inc. Oligonucleotides for enhanced modulation of protein kinase C expression
US5681747A (en) * 1992-03-16 1997-10-28 Isis Pharmaceuticals, Inc. Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
US5922686A (en) * 1992-03-16 1999-07-13 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of protein kinase C
US5882927A (en) * 1992-03-16 1999-03-16 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of protein kinase C
US5885970A (en) * 1992-03-16 1999-03-23 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against human protein kinase C
US5916807A (en) * 1992-03-16 1999-06-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against human protein kinase C
US5643780A (en) * 1992-04-03 1997-07-01 Isis Pharmaceuticals, Inc. Compositions and methods for modulating RNA activity through modification of the 5' cap structure of RNA
AU4774593A (en) * 1992-07-17 1994-02-14 Aprogenex, Inc. Multi reporter-labeled nucleic acid probes
US5521061A (en) * 1992-07-17 1996-05-28 Aprogenex, Inc. Enhancement of probe signal in nucleic acid-mediated in-situ hybridization studies
AU4775193A (en) * 1992-07-17 1994-02-14 Aprogenex, Inc. In situ detection of nucleic acids using 3sr amplification
US6174868B1 (en) 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
US6995146B2 (en) 1992-09-10 2006-02-07 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
US6423489B1 (en) 1992-09-10 2002-07-23 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of Hepatitis C virus-associated diseases
US6391542B1 (en) 1992-09-10 2002-05-21 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of Hepatitis C virus-associated diseases
US20040049021A1 (en) * 1992-09-10 2004-03-11 Anderson Kevin P. Compositions and mehtods for treatment of Hepatitis C virus-associated diseases
ATE202383T1 (de) * 1992-09-10 2001-07-15 Isis Pharmaceuticals Inc Zusammensetzungen und verfahren für die behandlung von mit hepatitis c viren assoziierten krankheiten
US5523389A (en) * 1992-09-29 1996-06-04 Isis Pharmaceuticals, Inc. Inhibitors of human immunodeficiency virus
US5985558A (en) 1997-04-14 1999-11-16 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
CA2110946A1 (en) * 1992-12-09 1994-06-10 Elazar Rabbani Induction of immunocompatibility by nucleic acid
WO1994023069A1 (en) 1993-03-26 1994-10-13 Gen-Probe Incorporated Detection of human immunodeficiency virus type 1
KR960703170A (ko) * 1993-06-23 1996-06-19 알버트 디. 프리센. 안티센스 올리고뉴클레오티드 및 인간면역결핍바이러스감염에서 그것의 치료적이용(antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection)
AU688364B2 (en) * 1993-07-19 1998-03-12 Gen-Probe Incorporated Oligonucleotides with activity against human immunodeficiency virus
US5739309A (en) * 1993-07-19 1998-04-14 Gen-Probe Incorporated Enhancement of oligonucleotide inhibition of protein production, cell proliferation and / or multiplication of infectious disease pathogens
JP3484197B2 (ja) 1993-09-03 2004-01-06 アイシス・ファーマシューティカルス・インコーポレーテッド アミン誘導化ヌクレオシドおよびオリゴヌクレオシド
US5510239A (en) * 1993-10-18 1996-04-23 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of multidrug resistance-associated protein
US5807838A (en) * 1994-09-23 1998-09-15 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of multidrug resistance-associated protein
US6399376B1 (en) 1993-11-05 2002-06-04 Isis Pharmaceuticals, Inc. Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
US5814619A (en) * 1994-04-08 1998-09-29 Isis Pharmacuticals, Inc. Oligonucleotide inhibition of P120
US6410518B1 (en) 1994-05-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US5744362A (en) * 1994-05-31 1998-04-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US5563255A (en) * 1994-05-31 1996-10-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US5656612A (en) * 1994-05-31 1997-08-12 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US20060142236A1 (en) * 1994-05-31 2006-06-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US20030119769A1 (en) * 1994-05-31 2003-06-26 Monia Brett P Antisense oligonucleotide modulation of raf gene expression
KR100211178B1 (ko) * 1994-05-31 1999-07-15 파샬 비. 린네 라프유전자 발현의 안티센스 올리고뉴클레오티드 조절
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6090626A (en) * 1994-05-31 2000-07-18 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of raf gene expression
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5733781A (en) * 1994-07-19 1998-03-31 Gen-Probe Incorporated Oligonucleotides and methods for inhibiting propagation of human immunodeficiency virus
US20030099959A1 (en) * 1995-04-12 2003-05-29 Kandimalla Ekambar R. Cooperative oligonucleotides
US6372427B1 (en) * 1995-04-12 2002-04-16 Hybridon, Inc. Cooperative oligonucleotides
US5985662A (en) * 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
US5856099A (en) * 1996-05-21 1999-01-05 Isis Pharmaceuticals, Inc. Antisense compositions and methods for modulating type I interleukin-1 receptor expression
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
US6111085A (en) * 1996-09-13 2000-08-29 Isis Pharmaceuticals, Inc. Carbamate-derivatized nucleosides and oligonucleosides
US6001991A (en) * 1996-10-04 1999-12-14 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression
US7235653B2 (en) * 1996-12-31 2007-06-26 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US6319906B1 (en) 1996-12-31 2001-11-20 Isis Pharmaceuticals Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US20040023917A1 (en) * 1996-12-31 2004-02-05 Bennett C. Frank Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US6077833A (en) * 1996-12-31 2000-06-20 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US6127533A (en) 1997-02-14 2000-10-03 Isis Pharmaceuticals, Inc. 2'-O-aminooxy-modified oligonucleotides
US6172209B1 (en) 1997-02-14 2001-01-09 Isis Pharmaceuticals Inc. Aminooxy-modified oligonucleotides and methods for making same
US6576752B1 (en) 1997-02-14 2003-06-10 Isis Pharmaceuticals, Inc. Aminooxy functionalized oligomers
AU6578298A (en) 1997-03-21 1998-10-20 President And Fellows Of Harvard College Antisense inhibition of angiogenin expression
JP2002510319A (ja) 1997-07-01 2002-04-02 アイシス・ファーマシューティカルス・インコーポレーテッド オリゴヌクレオチドの消化管を介したデリバリーのための組成物及び方法
US5972639A (en) * 1997-07-24 1999-10-26 Irori Fluorescence-based assays for measuring cell proliferation
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US5877309A (en) 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US20070149472A1 (en) * 1997-08-13 2007-06-28 Mckay Robert Antisense oligonucleotide compositions and methods for the modulation of jnk proteins
US6809193B2 (en) 1997-08-13 2004-10-26 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
WO1999035279A1 (en) 1998-01-12 1999-07-15 Georgetown University Medical Center G protein-related kinase mutants in essential hypertension
EP1469009A2 (de) * 1998-05-21 2004-10-20 Isis Parmaceuticals, Inc. Zusammensetzungen und Verfahren für nicht-parenterale Verabreichung von Oligonukleotiden
WO1999060167A1 (en) 1998-05-21 1999-11-25 Isis Pharmaceuticals, Inc. Compositions and methods for topical delivery of oligonucleotides
DK1077722T3 (da) 1998-05-22 2006-11-27 Ottawa Health Research Inst Fremgangsmåder og produkter til induktion af mukosaimmunitet
US6242589B1 (en) 1998-07-14 2001-06-05 Isis Pharmaceuticals, Inc. Phosphorothioate oligonucleotides having modified internucleoside linkages
US6867294B1 (en) * 1998-07-14 2005-03-15 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6277967B1 (en) 1998-07-14 2001-08-21 Isis Pharmaceuticals, Inc. Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages
US6077709A (en) 1998-09-29 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of Survivin expression
US6335194B1 (en) 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
CN1273478C (zh) * 1999-02-12 2006-09-06 三共株式会社 新型核苷及低聚核苷酸类似物
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
JP4151751B2 (ja) * 1999-07-22 2008-09-17 第一三共株式会社 新規ビシクロヌクレオシド類縁体
US6147200A (en) * 1999-08-19 2000-11-14 Isis Pharmaceuticals, Inc. 2'-O-acetamido modified monomers and oligomers
AU2001276691A1 (en) * 2000-08-03 2002-02-18 Matsushita Electric Industrial Co., Ltd. Brushless motor and method of manufacturing the brushless motor
US20030096770A1 (en) * 2001-07-11 2003-05-22 Krotz Achim H. Enhancement of the stability of oligonucleotides comprising phosphorothioate linkages by addition of water-soluble antioxidants
KR100991644B1 (ko) 2001-08-17 2010-11-02 콜리 파마슈티칼 게엠베하 활성이 개량된 조합 모티프 면역자극성 올리고뉴클레오티드
PT1470144E (pt) * 2002-02-01 2009-02-10 Univ Mcgill Oligonucleótidos incluindo segmentos alternantes e as suas utilizações
US20030191075A1 (en) * 2002-02-22 2003-10-09 Cook Phillip Dan Method of using modified oligonucleotides for hepatic delivery
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
EP2241325B1 (de) 2002-10-29 2012-02-08 Coley Pharmaceutical Group, Inc. Verwendung von CPG Oligonukleotide zur Behandlung von Hepatitis C Virus Infektion
JP2006512927A (ja) 2002-12-11 2006-04-20 コーリー ファーマシューティカル グループ，インコーポレイテッド ５’ｃｐｇ核酸およびその使用方法
WO2004071453A2 (en) * 2003-02-13 2004-08-26 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of pouchitis
JP2004283024A (ja) * 2003-03-19 2004-10-14 Junsei Chemical Co Ltd 新規アンチセンスオリゴヌクレオチド及び抗ｈｉｖ剤
US7635560B2 (en) * 2003-04-17 2009-12-22 Genesis Group Inc. Pygopus in diagnosis and treatment of cancer
DK1624936T3 (da) * 2003-05-16 2010-03-15 Univ Laval CNS-chloridmodulering og anvendelser deraf
US7960355B2 (en) * 2003-05-23 2011-06-14 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of the expression of B7 protein
US7897582B2 (en) * 2003-05-23 2011-03-01 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
SG123799A1 (en) 2003-10-30 2006-07-26 Coley Pharm Gmbh C-class oligonucleotide analogs with enchanced immunostimulatory potency
JP5838017B2 (ja) 2003-12-03 2015-12-24 コーダ セラピューティクス， インコーポレイテッド コネキシンに対して標的化されたアンチセンス化合物およびその使用方法
JP2007537167A (ja) * 2004-05-14 2007-12-20 ユニヴェルシテ ラヴァル ホスホリパーゼｃガンマの調節、並びにそれによる疼痛及び侵害受容の制御
EP1766015A4 (de) * 2004-06-09 2008-10-01 Univ Mcgill Für acetylcholin-gesteuerte chloridkanal-untereinheiten aus caenorhabditis elegans codierende polynukleotide
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
EP2510938A1 (de) 2005-02-03 2012-10-17 Coda Therapeutics Limited Anti-Connexin-Verbindungen und deren Verwendung zur Behandlung von Gefässkrankheiten
EP2057284A4 (de) * 2006-08-04 2011-06-29 Isis Pharmaceuticals Inc Zusammensetzungen und verfahren zur modulation von jnk-proteinen
EP2056845B1 (de) 2006-08-08 2017-10-11 Rheinische Friedrich-Wilhelms-Universität Bonn Struktur und verwendung von 5'-phosphat-oligonukleotiden
JP5960944B2 (ja) * 2006-11-15 2016-08-02 コーダ セラピューティクス， インコーポレイテッド 創傷治癒のための改善された方法および組成物
CA2672220A1 (en) 2006-12-11 2008-06-19 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
US20100279921A1 (en) * 2007-12-11 2010-11-04 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
AU2008335717A1 (en) 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
CA2710387A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of fibrotic conditions
US20110144182A1 (en) * 2007-12-21 2011-06-16 David Lawrence Becker Treatment of surgical adhesions
US9035037B2 (en) * 2007-12-21 2015-05-19 Coda Therapeutics, Inc. Medical devices
US20110217313A1 (en) * 2007-12-21 2011-09-08 Becker David L Treatment of orthopedic conditions
JP2011507862A (ja) * 2007-12-21 2011-03-10 コーダ セラピューティクス， インコーポレイテッド 異常瘢痕または過剰瘢痕の治療のための抗コネキシン４３ポリヌクレオチドの使用
JP2011507857A (ja) 2007-12-21 2011-03-10 コーダ セラピューティクス， インコーポレイテッド 線維症性の状態の処置のためのコネキシン４３の阻害剤の使用
US20110038920A1 (en) * 2008-01-07 2011-02-17 Ryoichi Mori Wound healing compositions and treatments
WO2009141146A1 (en) 2008-05-21 2009-11-26 Gunther Hartmann 5' triphosphate oligonucleotide with blunt end and uses thereof
US20110223204A1 (en) * 2008-06-04 2011-09-15 Bradford J Duft Treatment of pain with gap junction modulation compounds
US20120128673A1 (en) 2009-05-20 2012-05-24 Schering Corporation Modulation of pilr receptors to treat microbial infections
EP2513308B1 (de) 2009-12-17 2017-01-18 Merck Sharp & Dohme Corp. Modulation von pilr zur behandlung immunerkrankungen
EP2508530A1 (de) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Reinigung von triphosphorylierten Oligonucleotiden mit Einfang-Tags
DK3505528T3 (da) 2011-04-21 2021-02-08 Ionis Pharmaceuticals Inc Modulation af hepatitis-b-virus (hbv)-ekspression
CA2868534A1 (en) 2012-03-27 2013-10-03 Coda Therapeutics, Inc. Compositions and treatments based on cadherin modulation
EP2712870A1 (de) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Neuartige RIG-I-Liganden und Herstellungsverfahren dafür
US9156896B2 (en) 2013-03-15 2015-10-13 Coda Therapeutics, Inc. Wound healing compositions and treatments
US9708360B2 (en) 2013-09-30 2017-07-18 Geron Corporation Phosphorodiamidate backbone linkage for oligonucleotides
US10465188B2 (en) 2014-08-22 2019-11-05 Auckland Uniservices Limited Channel modulators
CN107207577B (zh) 2014-09-05 2021-11-09 Rsem有限合伙公司 用于治疗和预防炎症的组合物和方法
EP3954993A1 (de) 2015-02-04 2022-02-16 Bristol-Myers Squibb Company Verfahren zur auswahl therapeutischer moleküle
CN107922946A (zh) 2015-02-04 2018-04-17 霍夫曼-拉罗奇有限公司 Tau反义低聚物及其用途
EP3615575A4 (de) 2017-04-28 2021-01-13 Auckland Uniservices Limited Verfahren zur behandlung von neuartigen konstrukten
WO2019093649A1 (ko) 2017-11-10 2019-05-16 주식회사 엘지화학 신규한 화합물 및 이를 이용한유기 발광 소자

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959463A (en) * 1985-10-15 1990-09-25 Genentech, Inc. Intermediates
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
EP0331939B1 (de) * 1988-02-16 2001-11-14 Greatbatch Gen-Aid, Ltd Modifizierte Zellen mit Resistenz gegen Retroviralinfektionen
WO1989008146A1 (en) * 1988-02-26 1989-09-08 Worcester Foundation For Experimental Biology Inhibition of htlv-iii by exogenous oligonucleotides
DE3907562A1 (de) * 1989-03-09 1990-09-13 Bayer Ag Antisense-oligonukleotide zur inhibierung der transaktivatorzielsequenz (tar) und der synthese des transaktivatorproteins (tat) aus hiv-1 und deren verwendung
FR2648045B1 (fr) * 1989-06-13 1991-09-27 Centre Nat Rech Scient Composes oligonucleotidiques anomeres alpha inhibant la replication des retrovirus

Also Published As

Publication number Publication date
AU651593B2 (en) 1994-07-28
AU7882691A (en) 1991-12-10
NO924258D0 (no) 1992-11-05
FI925103A0 (fi) 1992-11-10
DE69131422T2 (de) 1999-10-28
HU9203538D0 (en) 1993-03-29
JPH06500005A (ja) 1994-01-06
EP0527916A1 (de) 1993-02-24
US5591600A (en) 1997-01-07
NO924258L (no) 1992-11-05
EP0527916B1 (de) 1999-07-07
KR0149680B1 (ko) 1998-08-17
EP0527916A4 (de) 1994-04-06
FI925103A (fi) 1992-11-10
JPH0832242B2 (ja) 1996-03-29
HUT62912A (en) 1993-06-28
US5166195A (en) 1992-11-24
BR9106440A (pt) 1993-05-18
ATE181960T1 (de) 1999-07-15
WO1991018004A1 (en) 1991-11-28
CA2082631A1 (en) 1991-11-12

Similar Documents

Publication Publication Date Title
DE69131422D1 (de) Gegensinnige hemmer des humanen immunmangel virus (hiv)
ATE317432T1 (de) Hiv-spezifische oligonukleotide und verfahren zu deren verwendung
ATE318273T1 (de) Zuckermodifizierte oligonukleotide zum erkennen und steuern der genexpression
FI951600A0 (fi) Terapeuttinen HIV:n vastainen oligonukleotidi ja lääkeaine
KR930700525A (ko) 인체 면역결핍 바이러스의 안티센스 억제제
BR9206026A (pt) Análogo de oligonucleotídio, processo para modular a produção ou atividade de uma proteína em um organismo, e, processo para proteger um análogo de oligonucleotídio ou nucleosídio bifuncional
ATE202383T1 (de) Zusammensetzungen und verfahren für die behandlung von mit hepatitis c viren assoziierten krankheiten
NO924225L (no) Modulering av genekspressjon ved inngrep med rna sekundaerstruktur
DE68925278D1 (de) Hemmung von htlv-iii durch exogene oligonukleotide
FI930658A (fi) Oligonukleotider foer modulering av effekten av cytomegalovirusinfektioner
DE69432586D1 (de) Methode zum generieren von einzelsträngigen dna molekülen
IT1094934B (it) Vettore di trasferimento per dna ricombinante,microorganismo contenente un gene derivato da un organismo superiore,e procedimento per ottenerlo
KR960015265B1 (en) Modulation of gene expression through interference with rna secondary structure
DE69232351D1 (de) Ribozymstruktur die von den genomischen rns des hepatitis delta virus abgeleitet ist
ATE83926T1 (de) Antivirale anwendung von alpha-oligonucleotiden.

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee